Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 August 2019 | Story Leonie Bolleurs | Photo Anja Aucamp
Jaco Marais, Programme Director, and Dr Eduan Kotzé
Jaco Marais, Programme Director, and Dr Eduan Kotzé, Academic Head of the Department of Computer Science and Informatics. Dr Kotzé believes the partnership with IoT.nxt will expose UFS staff and students to new and creative ways of thinking.

UFS information technology students will get exposure to the very latest developments in data science, after a recent exciting partnership was announced between the university and Internet of Things company, IoT.nxt – described by CNBC Africa as “a world leader in technological innovations.”

“The partnership with IoT.nxt will open new opportunities for our students and staff, not only to work with one of the most innovative companies in the country, but also to be exposed to new and creative ways of thinking, all in preparation for the 4th Industrial Revolution (4IR),” says Dr Eduan Kotzé, Academic Head of the UFS Department of Computer Science and Informatics.

“We also believe the partnership will strengthen our academic programme, especially in data science, and prepare our students to be ready for the ever-changing world of technology.”

He explains that it is a huge task to stay at the forefront of technological development. “IoT.nxt's involvement will help us to continually expose our students to trendsetting technologies that is applicable in the industry. It will also ensure that our graduates have the neccessary skills when they enter the job market. In doing so, our curriculum will remain relevant and keep up with new developments in the IT industry,” says Dr Kotzé.

UFS IT excellence

The Department of Computer Science and Informatics at the University of the Free State is widely regarded as one of the best IT departments at a tertiary institution in South Africa. Dr Kotzé believes the fact that we are one of only a few universities who present data science as an undergraduate qualification, followed by an honours qualification, provides us with a competitive edge and differentiates us from other institutions.

“We are also the only university offering a Bachelors Degree in Computer Information Systems aiming to deliver entrepreneurship in technology to make South Africa a role player in the IT industry,” says Dr Kotzé.

Job-ready graduates

He believes the planned short courses will expose students to the latest technology. He is also convinced that the opportunity to become accustomed to the workings of a successful IT company through holiday work, will have a very positive impact on the job readiness of the department’s graduates.

“Because of the pace at which technology is evolving, it is crucial that anyone in the IT industry is already in contact with industry entities that are at the top of the wave, such as IoT.nxt,” says Dr Kotzé.

According to Nico Steyn, IoT.nxt CEO, the support of education drives in the field of technology has been a key focus of his company. Steyn says IoT.nxt selected the UFS for this partnership because it views the university as one of the leading education institutions in this field. There are also UFS graduates among the co-founders.

Direct contact with pioneers

Steyn believes that there is an industry-wide shortage of qualified people in South Africa, and a growing demand for students to graduate with a qualification that meets the requirements of businesses. “Our company, and the vibrant broader technology industry in South Africa, needs such graduates. Through our partnership with the UFS, we will aim to drive interest in this career,” Steyn says.

The partnership with IoT.nxt is one of several industry partnerships that have been entered into by the UFS Department of Computer Science and Informatics over the past few years. “In the IT industry, it is crucial that our curriculum is constantly adapted to remain relevant in a rapidly changing landscape. The relevant skills are determined by the industry and it is therefore a huge advantage to have direct contact with pioneers in that sector,” says Dr Kotzé.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept